Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 1, n. 3.1, p. s128, 2017. DOI: 10.25251/skin.1.supp.127. Disponível em: https://skin.dermsquared.com/skin/article/view/81. Acesso em: 10 apr. 2025.